Drugs marketed by parallel traders are products of original manufacturers, often produced at the same plant for the medicines of local origin. The products for parallel trade are either absolutely identical or contain very small differences in color and excipients. Differences that regulators check for lack of therapeutic consequences. If a manufacturer / a marketing authorization holder criticizes a parallel marketed product, he actually criticizes his own product. The proliferation of each of these drugs is authorized by the national drug agency decision. All products supplied by parallel traders are subject to exactly the same safety provisions as products already positioned on the market. Therefore, there is no additional risk of using drugs imported by parallel distributors. The word "parallel" means only that the supply / sale and marketing of a medicinal product is done outside the distribution network of the manufacturer and his licensees (authorized representatives).